A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Long-Acting Injectable Formulation of Vanoxerine (Vanoxerine Consta 394.2 mg) for Cocaine Relapse Prevention

Journals Menu

Follow SCIRP

ISSN Print: 2162-2000
ISSN Online: 2162-2019
www.scirp.org/journal/wjns
E-mail: wjns@scirp.org

"A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Long-Acting Injectable Formulation of Vanoxerine (Vanoxerine Consta 394.2 mg) for Cocaine Relapse Prevention"
written by Sead Kadric, Hanns Mohler, Olli Kallioniemi, Karl Heinz Altmann,
published by World Journal of Neuroscience, Vol.9 No.3, 2019

has been cited by the following article(s):

[1]	The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors
	Nature Cancer, 2024

[2]	The dopamine inhibitor GBR12909 improves attention and compulsive behaviour in female rats
	bioRxiv, 2023

[3]	Rate Dependent Effects of Pharmacological Manipulation of Dopaminergic System on 5C-CPT Performance Measures
	2022

[4]	Kokain ile ilişkili patolojiler
	Current Addiction Research, 2021

[5]	New drugs, old targets: tweaking the dopamine system to treat psychostimulant use disorders
	2021

[6]	Ahead of print


[7]	Blocking cancer stem cell functions in colon tumors using a drug initially developed to treat cocaine addiction

Follow SCIRP

[1]	New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders Annual Review of Pharmacology and Toxicology, 2021 DOI:10.1146/annurev-pharmtox-030220-124205